Proxibarbital
Proxibarbital (Ipronal) is a barbiturate derivative synthesized in 1956. It has anti-anxiety properties and in contrast to most barbiturates almost without hypnotic action.[1]
Clinical data | |
---|---|
Other names | Proxibarbital, Centralgol, Ipronal, 5-Allyl-5-(β-hydroxypropyl)barbituric acid |
ATC code | |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
ECHA InfoCard | 100.018.004 |
Chemical and physical data | |
Formula | C10H14N2O4 |
Molar mass | 226.229 g/mol g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
|
It was also used in the treatment of migraine headaches in a similar manner to butalbital.[2]
Valofane isomerises to Proxibarbal in vivo.
References
- Zajdel, P.; Kulig, K.; Zejc, A. (2008). Zejc, A.; Gorczyca, M. (eds.). Chemia leków, podręcznik dla studentów farmacji i farmaceutów (in Polish). Warszawa, Poland. ISBN 978-83-200-3652-7.
- Sulman, F. G.; Pfeifer, Y.; Tal, E. (1976). "Migraine therapy by enzyme induction with proxibarbital". Therapie der Gegenwart (in German). 115 (12): 2088–2103. PMID 14412.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.